Retina:玻璃体视网膜病变患者进行气压性视网膜固定手术结果!

2017-11-21 cuiguizhong MedSci原创

加州大学戴维斯分校眼科与视觉科学系的Emami-Naeini P近日在Retina发表了他们的一项工作,他们对进行过气压性视网膜固定手术的玻璃体视网膜病变患者,进行手术后解剖和视力结果研究。

加州大学戴维斯分校眼科与视觉科学系的Emami-Naeini P近日在Retina发表了他们的一项工作,他们对进行过气压性视网膜固定手术的玻璃体视网膜病变患者,进行手术后解剖和视力结果研究。

他们纳入了2002年11月至2016年6月期间,在单一学术机构中接受玻璃体视网膜治疗的198例眼睛(198名患者),这些患者都接受了气压性视网膜手术。主要的评价指标是单次手术成功情况、最终解剖复位成功情况、治疗3个月和6个月后的视力恢复情况。

结果他们发现,单次手术成功率在3个月时为63.6%,6个月时为59.5%。最终解剖复位成功率在3个月和6个月时分别达到92.9%(184例)和96.6%(143例)。视力最小角度的对数从起始的0.72±0.1(约20 / 100 Snellen)改善至6个月时的0.36±0.06(20 / 40 Snellen)(P <0.001)。第一年和第二年的随访调查发现,解剖成功率或视力结果没有显着的差异(P> 0.50)。同时发现,单次手术成功情况与脱离的程度相关(P = 0.01)。视力结果与起始状态(P = 0.032)和进行手术的次数(P <0.001)相关。

因此,他们认为,气压性视网膜固定手术的解剖和视觉效果与以前文献报道的相当。

原文出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1913850, encodeId=34181913850d4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 13 21:39:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793299, encodeId=ff851e93299fd, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Nov 23 12:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269974, encodeId=fea612699e40f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413917, encodeId=d9b8141391e27, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496216, encodeId=586514962160c, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263252, encodeId=5692263252d7, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Wed Nov 22 07:00:59 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263208, encodeId=47622632087e, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Nov 21 23:27:54 CST 2017, time=2017-11-21, status=1, ipAttribution=)]
    2018-04-13 ysjykql
  2. [GetPortalCommentsPageByObjectIdResponse(id=1913850, encodeId=34181913850d4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 13 21:39:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793299, encodeId=ff851e93299fd, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Nov 23 12:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269974, encodeId=fea612699e40f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413917, encodeId=d9b8141391e27, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496216, encodeId=586514962160c, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263252, encodeId=5692263252d7, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Wed Nov 22 07:00:59 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263208, encodeId=47622632087e, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Nov 21 23:27:54 CST 2017, time=2017-11-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1913850, encodeId=34181913850d4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 13 21:39:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793299, encodeId=ff851e93299fd, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Nov 23 12:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269974, encodeId=fea612699e40f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413917, encodeId=d9b8141391e27, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496216, encodeId=586514962160c, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263252, encodeId=5692263252d7, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Wed Nov 22 07:00:59 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263208, encodeId=47622632087e, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Nov 21 23:27:54 CST 2017, time=2017-11-21, status=1, ipAttribution=)]
    2017-11-23 zutt
  4. [GetPortalCommentsPageByObjectIdResponse(id=1913850, encodeId=34181913850d4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 13 21:39:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793299, encodeId=ff851e93299fd, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Nov 23 12:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269974, encodeId=fea612699e40f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413917, encodeId=d9b8141391e27, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496216, encodeId=586514962160c, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263252, encodeId=5692263252d7, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Wed Nov 22 07:00:59 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263208, encodeId=47622632087e, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Nov 21 23:27:54 CST 2017, time=2017-11-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1913850, encodeId=34181913850d4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 13 21:39:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793299, encodeId=ff851e93299fd, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Nov 23 12:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269974, encodeId=fea612699e40f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413917, encodeId=d9b8141391e27, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496216, encodeId=586514962160c, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263252, encodeId=5692263252d7, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Wed Nov 22 07:00:59 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263208, encodeId=47622632087e, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Nov 21 23:27:54 CST 2017, time=2017-11-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1913850, encodeId=34181913850d4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 13 21:39:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793299, encodeId=ff851e93299fd, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Nov 23 12:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269974, encodeId=fea612699e40f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413917, encodeId=d9b8141391e27, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496216, encodeId=586514962160c, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263252, encodeId=5692263252d7, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Wed Nov 22 07:00:59 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263208, encodeId=47622632087e, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Nov 21 23:27:54 CST 2017, time=2017-11-21, status=1, ipAttribution=)]
    2017-11-22 Drhzm308

    谢谢.学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1913850, encodeId=34181913850d4, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Fri Apr 13 21:39:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793299, encodeId=ff851e93299fd, content=<a href='/topic/show?id=5400153e639' target=_blank style='color:#2F92EE;'>#Retina#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15376, encryptionId=5400153e639, topicName=Retina)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Thu Nov 23 12:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269974, encodeId=fea612699e40f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413917, encodeId=d9b8141391e27, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496216, encodeId=586514962160c, content=<a href='/topic/show?id=bab46858ee3' target=_blank style='color:#2F92EE;'>#玻璃体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68587, encryptionId=bab46858ee3, topicName=玻璃体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47bd9248134, createdName=yykkxiaodou, createdTime=Thu Nov 23 13:39:00 CST 2017, time=2017-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263252, encodeId=5692263252d7, content=谢谢.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Wed Nov 22 07:00:59 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=263208, encodeId=47622632087e, content=学习了.好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Nov 21 23:27:54 CST 2017, time=2017-11-21, status=1, ipAttribution=)]
    2017-11-21 1ddf0692m34(暂无匿称)

    学习了.好文章

    0

相关资讯

Exp Eye Res:猪体内磷脂玻璃体液中的区域分布研究

美国路易斯维尔大学眼科与视觉科学系的Borchman D教授团队近日在Exp Eye Res杂志上发表了他们最新的一项工作,他们研究了猪体内磷脂玻璃体液中的区域分布情况。

2015NICE技术评估指南:玻璃体腔内注射地塞米松治疗糖尿病性黄斑水肿(TA349)发布

2015年7月22日,英国国家卫生与临床优化研究所 (NICE)发布玻璃体腔内注入地塞米松治疗糖尿病性黄斑水肿的技术评估指南。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

Int Ophthalmol:急性后玻璃体脱离患者发生多发性视网膜撕裂的危险因素分析

该研究用于评估急性后玻璃体脱落患者发生多发性视网膜撕裂的可能危险因素。三百七十六名患者持续表现出眼前漂浮物与潮热症状,对眼前漂浮物与潮热症状的持续时间、闪烁、视网膜分离的家族史、外周视网膜退行性变、晶状体状态、近视、烟粉尘、视网膜或玻璃体出血等因素与视网膜撕裂的关系进行探究分析。

Invest Ophthalmol Vis Sci:Fc区域对抗VEGF药物在玻璃体半衰期中的作用!

韩国首尔国立大学医学院眼科系的Joo K近日在Invest Ophthalmol Vis Sci杂志发表了一篇文章,他们研究了可结晶的片段(Fc)在眼内蛋白药物药代动力学中的作用。

Brit J Ophthal:上海九院汪朝阳教授发现玻璃体切割术间使用罗哌卡因疼痛和出血风险更低

为了比较1%罗哌卡因(Ropivacaine), 0.75%布比卡因(Bupivacaine), 2%利多卡因以及0.75%丁哌卡因和2%利多卡因(bupi+lido)的混合制剂在玻璃体切除术球周麻醉的术中和术后临床特性。中国上海交通大学附属第九人民医院汪朝阳教授和新华医院的研究人员开展了一项前瞻性随机双盲临床研究。该研究于2月7日在 British Journal of Ophthal